Analysis by Kelly Emrick, DHSc, PhD, MBA, BSRT(ARRT)R
Medical Cost Trend 2027 · Behind the Numbers Analysis
Anatomy of a Nine Percent Trend
Structural inflators, constrained deflators, and the strategic implications for payers, self-funded employers, and imaging service lines. Source under analysis: PwC Health Research Institute, Medical Cost Trend: Behind the Numbers 2027 (June 11, 2026).
9.0%Group market trend 2027
8.5%Individual ACA trend 2027
17 yrsHighest sustained level since 2010
88%Provider win rate at IDR
Prepared by Kelly Emrick, DHSc, PhD, MBA, BSRT(ARRT)R · June 2026
The defining feature of the 2027 outlook is not the magnitude of the number but the character of its drivers: structural, multi-channel, and largely insensitive to the deflators that contained trend in the prior decade.
Commercial Medical Cost Trend, 2017 to 2027
Group trend climbed from a 5.5% trough in 2018 to a projected 9.0% in 2027. Toggle the series to compare markets.
Why 2027 Is Different
1
The leading inflator works through coded severity, not price or volume. AI-enabled documentation raises paid amounts per claim without changes to contracted rates or care intensity, evading both rate negotiation and utilization management.
2
Historical deflators are spent. Generics, biosimilars, and site-of-care migration are now embedded in the baseline. Payers depend on internal levers whose collective capacity cannot offset structural inflators in a single pricing cycle.
3
IDR arbitration matured into a reimbursement channel. An 88% provider win rate across 2.68 million categorized disputes, with imaging at 23.6% of volume, directly shapes radiology economics.
2026 restated upward: Group from 8.5% to 9.0%, Individual from 7.5% to 8.5%. Actuarial projections undershot realized experience, lending credibility to the elevated 2027 figure.
Methodology at a Glance
27Health plans surveyed (Apr–May 2026)
103M+Employer-sponsored lives covered
8MIndividual ACA marketplace lives
3Cost levers: price, utilization, mix
Weighted average by self-reported covered lives; Group and Individual kept separate. Estimates exclude population morbidity and enrollment mix shifts, so the headline trend describes the underlying cost of care, not the premium experience of any actual purchaser. Supplemented with PurpleLab claims, Blue Health Intelligence and BCBSA coding analyses, IQVIA medicine use data, Trilliant Health behavioral data, and CMS public use files.
The Five Inflators Behind the 9% Trend
Ranked by expected upward variance contributed relative to historical trend. Select a card to expand the evidence base and structural mechanism.
How Plans Ranked the Pressure
Share of surveyed plans placing each dynamic among their top concerns for 2027.
Severity capture has become a third channel of cost growth that bypasses both the negotiating table and the prior authorization queue.
Constrained Deflators: The Payer Lever Framework
External deflators (generics, biosimilars, site-of-care migration) remain active but are embedded in the baseline. What remains is the set of levers plans directly control, ranked by realizable value and speed to impact.
Faster impactSlower, structural impact
I
Move control upstream
Shift payment integrity from post-payment recovery to pre-payment validation of high-dollar claims, DRG shifts, and provider-level severity drift. Accuracy, not denial volume, is the goal.
II
Use precision, not breadth
Retire low-yield prior authorizations (voluntary commitments already removed 11% of PAs, some 6.5 million requests) and concentrate review on advanced imaging, elective musculoskeletal procedures, and genetic testing.
III
Demand demonstrated value
Defund care management and vendor programs that cannot show avoided utilization. Do not expand value-based contracts that fail to produce net savings after incentive payments.
The likely 2027 goal is mitigation, not reversal. The named levers reduce leakage and avoidable cost at the margin, while the inflators operate on the base. Absent structural intervention in provider concentration, drug pricing, or the IDR award pattern, nine percent may be the floor rather than the ceiling.
No Surprises Act IDR: A Durable Reimbursement Channel
The statute protected members from surprise balance bills but inverted the original fiscal expectation. CBO assumed roughly 17,000 disputes per year; realized volume exceeded that by more than two orders of magnitude.
4.8MDisputes filed through end of 2025
2.6MFiled in 2025 alone
88%Provider win rate, H1 2025 determinations
56%Of filings from just four provider groups
Dispute Composition by Service Category
2.68 million categorized federal IDR disputes. Emergency services and imaging together account for nearly 60% of volume.
Why This Inflator Is Durable
1
Industrialized arbitration. A small number of provider organizations initiated 99.9% of H1 2025 disputes. This is an operational revenue capability, not diffuse clinical grievance.
2
The judicial check has narrowed. Federal courts in California and Florida dismissed insurer suits against HaloMD and Radiology Partners in April 2026, holding the statute sharply limits second-guessing of IDR awards.
3
Reform addresses friction, not awards. CMS’s May 2026 changes (lower fees, batching flexibility, IDR Gateway, payer registry, five-day eligibility determinations) improve throughput without touching the provider-favorable award pattern.
Radiology emphasis: imaging is the second-largest dispute category at 23.6%, dominated by professional component disputes. Awards persistently exceed the qualifying payment amount, directly raising realized unit cost of interpretation services for commercial payers.
The Individual ACA Market Reset
Enhanced premium subsidy expiration reset the baseline. PwC normalizes morbidity and composition shifts out of its 8.5% trend, which is methodologically correct but means the headline materially understates the premium increases members will actually experience.
Average Monthly Premium After Tax Credits
Net member premium more than doubled in two years, from $81 in 2024 to $178 in 2026.
Enrollment and Rate Action
↓
Plan selections fell from 24.3M to 23.1M between 2025 and 2026, with early 2026 analysis showing national enrollment down roughly 17% through April and disenrollment reaching 21% in federal marketplace states.
%
Average 2026 rate actions ran roughly 26%, with 2.9 to 6.5 points attributed to morbidity deterioration and total expected action in the 20% to 40% range once subsidy expiration effects are included.
⇅
Wide state variation, under 10% to nearly 70%, as state subsidy wrap programs moderated disruption in some markets. Healthier members lapsing coverage mechanically worsens the residual risk pool: the classic adverse selection spiral.
Implications for Imaging and Radiology Service Lines
The source addresses payers and employers, but its findings bear directly on imaging economics, and they cut in both directions. For imaging leaders, the report is, on balance, a map of opportunity.
Transparency, steerage, and precision utilization management all reward efficient, contracted, lower-cost sites of care, while the IDR dynamic that inflates payer cost simultaneously invites a flight to in-network imaging partners who can demonstrate value.
Critical Appraisal, Trends to Watch, and Sources
Methodological Cautions
Expert elicitation, not an econometric forecast: a weighted synthesis of actuarial expectations with no stated confidence intervals.
The same actuaries’ 2026 projections required upward restatement, though the willingness to update against realized experience is a strength.
The inflator ranking is qualitative; relative magnitudes of the five inflators are not formally decomposed.
Several supporting analyses originate from payer-aligned organizations with an institutional interest in the documentation-intensity narrative.
Scope excludes Medicare and Medicaid; morbidity normalization means figures describe underlying cost of care, not purchaser premium experience.
The nine-trillion-dollar 2035 projection is presented without methodology and should be treated as directional rhetoric.
Treat 9.0% as a central tendency with meaningful upside risk rather than a point estimate.
Trends to Watch
1
Public program spillover. Medicaid and post-subsidy strain raises uncompensated care and commercial rate demands (HCA attributed roughly $150M of Q1 2026 earnings reduction to subsidy expiration). MA prior authorization reform may narrow commercial UM flexibility. The 340B program grew from $6.6B (2010) to $43.9B (2021) in purchases, shaping site-of-care economics.
2
Cell and gene therapy migration. The ten most expensive US drugs are all gene therapies, several above $2M per administration. VERVE-102, an in vivo PCSK9 editor, cut LDL up to 62% in early 2026 data. A one-time therapy for hypercholesterolemia would convert episodic shock risk into mainstream spend and force rethinking of actuarial smoothing and stop-loss design.